Coppell Advisory Solutions’s AstraZeneca AZN Stock Holding History

Coppell Advisory Solutions’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.11M	Buy	21,183 +12,617	+147%	+$2.43M	2.42%	7
2025 Q4	$1.58M	Sell	8,566 -1,061	-11%	-$186K	0.16%	133
2025 Q3	$1.43M	Sell	9,627 -580	-6%	-$87.8K	0.15%	145
2025 Q2	$1.43M	Sell	10,207 -1,852	-15%	-$260K	0.17%	129
2025 Q1	$1.73M	Sell	12,059 -4,556	-27%	-$659K	0.24%	101
2024 Q4	$2.18M	Buy	16,615 +7,169	+76%	+$1M	0.3%	68
2024 Q3	$1.47M	Buy	9,446 +95	+1%	+$15.3K	0.22%	99
2024 Q2	$1.46M	Buy	+9,351	New	+$1.41M	0.24%	90
2023 Q4	$39.6K	Buy	294 +191	+185%	+$24.8K	0.01%	547
2023 Q3	$14K	Buy	103 +3	+3%	+$410	﹤0.01%	549
2023 Q2	$14.3K	Buy	+100	New	+$14.7K	﹤0.01%	620
2023 Q1	–	Sell	-103	Closed	-$14K	–	263
2022 Q4	$14K	Buy	+103	New	+$12.9K	﹤0.01%	556

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Coppell Advisory Solutions's AZN Position: Q1 2026 in Review

Coppell Advisory Solutions increased its AstraZeneca (AZN) stake by 147% in Q1 2026, buying an estimated $2.43M and bringing the position to 21,183 shares worth $4.11M. The position accounts for 2.42% of the portfolio, ranked #7.

Coppell Advisory Solutions first reported a position in AZN in Q4 2022 and has held it in 12 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Coppell Advisory Solutions held 21,183 shares of AstraZeneca worth $4.11M as of Q1 2026.
Coppell Advisory Solutions bought 12,617 AstraZeneca shares in Q1 2026, an estimated $2.43M.
AstraZeneca made up 2.42% of Coppell Advisory Solutions's portfolio in Q1 2026, its #7 holding.
Coppell Advisory Solutions first reported a position in AstraZeneca in Q4 2022 and has held it in 12 quarters since.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Coppell Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.